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Background: HIV latency is an obstacle for the eradication of HIV from infected individuals. Stable post-integration
latency is controlled principally at the level of transcription. The HIV trans-activating protein, Tat, plays a key
function in enhancing HIV transcriptional elongation. The HIV core promoter is specifically required for Tat-mediated
trans-activation of HIV transcription. In addition, the HIV core promoter has been shown to be a potential anti-HIV
drug target. Despite the pivotal role of the HIV core promoter in the control of HIV gene expression, the molecular
mechanisms that couple Tat function specifically to the HIV core promoter remain unknown.
Results: Using electrophoretic mobility shift assays (EMSAs), the TATA box and adjacent sequences of HIV essential
for Tat trans-activation were shown to form specific complexes with nuclear extracts from peripheral blood
mononuclear cells, as well as from HeLa cells. These complexes, termed pre-initiation complexes of HIV (PICH), were
distinct in composition and DNA binding specificity from those of prototypical eukaryotic TATA box regions such as
Adenovirus major late promoter (AdMLP) or the hsp70 promoter. PICH contained basal transcription factors
including TATA-binding protein and TFIIA. A mutational analysis revealed that CTGC motifs flanking the HIV TATA
box are required for Tat trans-activation in living cells and correct PICH formation in vitro. The binding of known
core promoter binding proteins AP-4 and USF-1 was found to be dispensable for Tat function. TAR RNA prevented
stable binding of PICH-2, a complex that contains the general transcription factor TFIIA, to the HIV core promoter.
The impact of TAR on PICH-2 specifically required its bulge sequence that is also known to interact with Tat.
Conclusion: Our data reveal that CTGC DNA motifs flanking the HIV TATA box are required for correct formation of
specific pre-initiation complexes in vitro and that these motifs are also required for Tat trans-activation in living cells.
The impact of TAR RNA on PICH-2 stability provides a mechanistic link by which pre-initiation complex dynamics
could be coupled to the formation of the nascent transcript by the elongating transcription complex. Together,
these findings shed new light on the mechanisms by which the HIV core promoter specifically responds to Tat to
activate HIV gene expression.Background
Latency of HIV contributes to viral persistence despite
current antiviral therapies, as well as to immune evasion
[1-4]. Post-integration latency is the most long-lived
source of latent HIV where the host cell genome harbors
a functional provirus that is transcriptionally silent [4,5].
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reproduction in any medium, provided the orterminal repeat (LTR) of the integrated viral genome,
pirates the host cell RNA polymerase II (Pol II) machin-
ery to initiate viral transcription. Transcriptional inter-
ference, chromatin structure and modification (e.g.
acetylation/deacetylation of histones), DNA methylation,
limitation of host factors (e.g. P-TEFb), and activation by
specific host cell factors (e.g. NF-κB, NFAT1) can all
contribute to the activation of HIV transcription [1,3,4].
The core promoter is ultimately the gateway for all sig-
nals activating HIV transcription, since it nucleates the
formation of Pol II pre-initiation complex (PIC) which is
a rate-limiting step in the initiation of transcription [6].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Wilhelm et al. Retrovirology 2012, 9:62 Page 2 of 19
http://www.retrovirology.com/content/9/1/62Once HIV transcription occurs, the HIV Tat gene
product can be expressed and plays an important role in
the exit from latency by driving a feed-forward loop to
fully activate viral transcription [7]. Tat acts by physically
interacting with a stem-loop structure of the nascent 5’
HIV RNA termed TAR. Tat binds to TAR in conjunction
with an essential cellular cofactor termed positive tran-
scription elongation factor b (P-TEFb), composed of
CDK9 and Cyclin T1 [8-10]. Recently published data
suggest that nascent TAR RNA can displace promoter-
bound transcription complexes containing an inhibitory
small non-coding RNA (7SK) that sequesters P-TEFb in
an inactive form [11]. Once in the active, 7SK free form,
P-TEFb is recruited by Tat into a complex with other
cellular elongation factors and co-factors termed the
super elongation complex (SEC) [12,13]. Tat acts within
SEC on Pol II, in part via phosphorylation of the c-
terminal domain (CTD) of Pol II, to potently increase
elongation rates of HIV transcription [14,15]. The HIV
trans-activator Tat thus drives an amplification loop dur-
ing the reactivation of latent HIV.
In addition to the essential role of TAR RNA in Tat ac-
tivity, a DNA element within the HIV core promoter has
been shown to be specifically required for Tat trans-acti-
vation [16-20]. Berkhout and Jeang published the first
demonstration that replacement of the HIV TATA box
region with other eukaryotic TATA box regions strongly
reduced Tat-activation with no pronounced effects on
basal transcription or transcriptional start site selection
[16]. Likewise, Olsen and Rosen found that minor nu-
cleotide changes within or immediately flanking the
TATA motif diminished Tat-mediated trans-activation
without affecting transcription initiation site or tran-
scriptional activation via the upstream NF-κB sites [19].
Lu et al. showed that the HIV TATA box and immedi-
ately flanking sequences are essential for the production
of non-processive transcripts that are targets of trans-ac-
tivation by Tat [18]. Montanuy et al. confirmed and
extended these findings, showing that the HIV TATA
box is required to enhance transcriptional elongation in
response to recruitment of the P-TEFb subunit, CDK9
[21]. Even in the context of a heterologous thymidine
kinase herpes simplex promoter where Tat is recruited
via DNA elements, the HIV TATA box region was
required for optimal Tat trans-activation [17]. Sequences
flanking the HIV TATA box, particularly those overlap-
ping a 3’ E-box that can bind cellular transcription factor
AP4, have been shown to be critical for Tat-trans-activa-
tion [20]. More recently AP4, a bHLH domain contain-
ing transcriptional factor, was shown not to be required
for Tat trans-activation, but instead to repress HIV tran-
scription in part by competing with TATA-binding pro-
tein (TBP) for the HIV core promoter [22]. Recruitment
of TBP to the HIV LTR is necessary, but not sufficient,for Tat trans-activation [23,24]. Molecular genetic stud-
ies indicate that TBP recognizes a CATA sequence ra-
ther than a canonical TATA sequence within the HIV
core promoter [25]. HIV Tat can physically interact with
TBP [26-28], although the requirement of sequences
surrounding the HIV TATA box in Tat trans-activation
suggests that cellular factors other than TBP must
recognize the core promoter in order for Tat to act upon
it. Importantly, a proof-of-principle that the HIV core
promoter represents a therapeutically useful target has
been provided using polyamides that bind specifically to
GC(T/A)GC motifs flanking the HIV TATA box [29].
These molecules repressed HIV replication in primary
lymphocytes without any apparent reduction in cell via-
bility [29]. Taken together, the above studies demon-
strate that the unique architecture of the HIV TATA
box and flanking sequences are essential for Tat trans-
activation. To distinguish Tat-responsive sequences from
the entire HIV core promoter, and for brevity, we refer
hereafter to these sequences as the TATA box and adja-
cent sequences of HIV essential for Tat trans-activation
(TASHET) (Figure 1).
TASHET plays a crucial role in the control of HIV gene
expression and latency; yet, the cellular complexes that
impart functional specificity upon it are completely un-
known. The identification of specific cellular TASHET-
binding complexes could potentially reveal drug targets
for therapies to flush out, or definitively silence, latent
virus in HIV infected individuals. Given the deepening
realization that core promoter binding complexes are
highly diverse [6,30-35], together with recent advances in
the experimental detection of endogenous pre-initiation
complexes [36], we have revisited TASHET function. Here,
we report the results of experiments designed to answer
three critical but unresolved questions: 1) Are cellular pre-
initiation complexes that recognize TASHET distinct from
those binding the other eukaryotic TATA elements such
as the prototypical Adenovirus major late promoter
(AdMLP)? 2) Precisely what cis-acting DNA sequences are
required for the formation of Tat-responsive pre-initiation
complexes? 3) What physical interactions account for the
functional dependence of the Tat/TAR axis on TASHET?
Results
Natural sequence variation of the TASHET element of the
HIV core promoter
The availability of extensive sequencing of HIV promoters
from clinical isolates provides a wealth of information
about the conservation of nucleotides that are important
for viral replication. To establish the sequence variation
within the HIV core promoter (Figure 1A and 1B), we
aligned HIV promoter sequences from the Los Alamos
HIV Sequence Database (http://www.hiv.lanl.gov). We fo-































































































Figure 1 Natural sequence variation of the HIV core promoter. (A) The HIV genome is shown in schematized form. The gene encoding the
viral trans-activating protein, Tat, is in black. The core promoter of the 5’ long terminal repeat (LTR) is in blue. (B) A schematized version of the
HIV promoter (5’ LTR) is shown with cellular transcription factors in grey. Viral Tat protein is shown in black interacting with the TAR stem-loop
RNA structure at the 5’ end of the nascent HIV transcript. The TATA box and adjacent sequences of HIV essential for Tat trans-activation (TASHET)
contain the TATA box (purple) and flanking sequences (blue). A question mark highlights a mechanistic missing link in our current understanding
of the specific requirement for TASHET in Tat trans-activation. (C) Natural sequence variation of TASHET (positions – 35 to – 14 relative to the
transcription start site) is shown. HIV sequences from the Los Alamos HIV Sequence Database (http://www.hiv.lanl.gov) were aligned, and the
weblogo algorithm (http://weblogo.berkeley.edu/) was used to generate a logo sequence in which the height of each nucleotide position
indicates sequence conservation. The height of different nucleotides at single position indicates their relative frequency.
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Tat trans-activation (TASHET). Nucleotides −33 to −16
with respect to the transcriptional start site displayed
mostly high levels of conservation while nucleotides flank-
ing this region displayed decreasing conservation. The
conservation of most nucleotides from −33 to −16 corre-
sponds well with the core promoter sequences defined by
several independent mutational studies to be essential for
Tat trans-activation [16-21,37]. Two nucleotides within
TASHET that display notably high variability include the
previously noted position −26 (T or A) within the TATAbox [38,39] and position −18 (T or C) within an E-box
element immediately downstream (Figure 1C). The con-
servation of TASHET sequences from naturally occurring
HIV isolates guided our design of mutations to identify
functionally important base-pairs throughout this study.
Host cell complexes formed on TASHET are distinct from
those forming on the AdMLP
We have recently reported electrophoretic mobility shift
assay (EMSA) conditions that are optimised to allow the
detection of endogenous RNA Pol II pre-initiation
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http://www.retrovirology.com/content/9/1/62complexes (PIC) [36]. To test experimentally whether
transcription complexes formed on the TASHET are dis-
tinct from those that form on the model AdMLP TATA
region, EMSAs were performed under conditions that
detect endogenous PIC with radiolabelled double-
stranded TASHET and equivalent oligonucleotides from
the AdMLP TATA region to probe the nuclear com-
plexes that recognize them. Radiolabelled TASHET
formed complexes with nuclear extracts from HeLa cells
(Figure 2A, lane 1). We applied a nomenclature for the
distinct TASHET-binding complexes based on the iden-
tification of their subunits as described below. Competi-
tion with a two hundred fold molar excess of unlabelled
TASHET prevented the formation of the majority of the
observed complexes, showing their specificity (Figure 2A,































Figure 2 TASHET of the HIV core promoter binds nuclear
complexes distinct from those binding the canonical
Adenovirus major late promoter (AdMLP). (A) Radiolabelled
oligonucleotides corresponding to the HIV core promoter were
incubated with HeLa nuclear extracts and the resulting complexes
were separated on a native polyacrylamide gel. Bound complexes
were analyzed by phosphorimaging. The binding reactions were
challenged by the addition of a 200 fold molar excess of unlabelled
HIV wt promoter (lane 2), or AdMLP (lane 3). Pre-initiation complexes
of HIV (PICH) and other HIV core promoter-binding cellular factors
are labelled at the left. n.s. indicates a non-specific complex. The free
probe is shown with an arrow at the bottom of the gel. (B) As in A
except that radiolabelled AdMLP was the probe. Specific complexes
are indicated with arrows in both panels.unlabelled AdMLP oligonucleotide had no significant im-
pact on the formation of the same complexes (Figure 2A,
lane 3). Conversely, radiolabelled AdMLP formed com-
plexes with HeLa cell nuclear factors that were distinct
from those binding the TASHET in their electrophoretic
mobility (Figure 2B, lane 1). These complexes were un-
affected by the addition of a two hundred fold molar ex-
cess of unlabelled TASHET DNA (Figure 2B, lane 2), but
were effectively blocked by the addition of unlabelled
AdMLP (Figure 2B, lane 3). We concluded that cellular
complexes distinct in composition and in DNA binding
specificity from those that recognize the equivalent TATA
box region from the prototype AdMLP recognize the
TASHET.Pre-initiation complexes of HIV (PICH) from HeLa cells
and from PBMCs specifically recognize TASHET in vitro
To further investigate the cellular complexes that specif-
ically recognize the TASHET element within the HIV
core promoter, we performed competition with the
equivalent TATA box region from the cellular hsp70
promoter. As with the AdMLP, (Figure 3, lane 5), the
hsp70 promoter was unable to compete for all com-
plexes binding the TASHET with the exception of
PICH-3 that showed a modest competition (Figure 3,
lane 6). The fact that complexes recognizing the
TASHET are distinct in DNA binding specificity from
those that recognize the cellular hsp70 TATA box region
lends further support for the atypical nature of these
complexes. Given the unusual nature of the TASHET-
binding complexes, we next tested whether they require
the TATA box itself for binding. Unlabelled competitor
DNA lacking a TATA box competed very poorly for
binding to PICH-3, and competed less effectively for
other complexes (Figure 3, lane 4 “TATAKO”) than the
wild type TASHET (Figure 3, lane 3). We concluded that
PICH-3 formation requires an intact TATA box to bind
to the HIV core promoter.
The HeLa cell model has been employed as a valuable
model to identify cellular transcription factors that con-
trol HIV transcription such as SP1 [40], NF-κB [41], and
P-TEFb [9]. To examine the suitability of the HeLa cell
system for the study of cellular complexes binding to
TASHET, we isolated nuclear extracts from activated
peripheral blood mononuclear cells (PBMC) from
healthy donors as these contain the physiological targets
for HIV infection CD4+ lymphocytes and monocytes.
EMSA assays were performed with PBMC nuclear
extracts and revealed complexes of indistinguishable
mobility and DNA binding specificity compared to those
from HeLa cell nuclear extracts (Figure 3, panel B, lanes
1–6 versus panel A lanes 1–6). The similarities between























































































- 17 87 18 37 61
- 2 93 60 7 -
- - 76 55 7 -
- - 60 49 14 12
- - 77 68 11 10
- 6 89 21 30 57
- 2 95 64 7 15
- - 80 56 3 5
- - 59 39 17 33











































Figure 3 Pre-initiation complexes of HIV (PICH) from PBMC and HeLa cells specifically recognize the intact HIV wt core promoter.
EMSAs were performed as in Figure 2. (A) HeLa nuclear extracts were used in binding reactions that were challenged by the addition of a 200
fold molar excess of the indicated unlabelled promoter competitors (lane 2 to 6). Lane 1 contains no competitor (−). Lane 2 contains a scrambled
non specific competitor. The upper panel shows complexes in the EMSA reaction. Pre-initiation complexes of HIV (PICHs) and a non-specific
complex are indicated by arrows at the left. Quantifications of EMSA bands are displayed in the table in the lower panel, expressed as the
percentage of reduction of each complex’s intensity upon competition. Complexes whose intensities are reduced by 50% or more by the
addition of unlabelled competing oligonucleotides are highlighted in red. (B) As in A except that nuclear extracts from activated PBMC were
used. (C) Quantification of EMSA band intensities from panel A is shown in graphic form. The intensity of the most abundant PICH in the control
lane (panel A lane 1) has been set to 100%. Red color is used to highlight reduction of 50% or more for each complex relative to its level in the
control lane (−). Shades of grey are used to distinguish each PICH. Relative band intensity is given on the vertical Y-axis, complexes are indicated
on the right (Z-axis), and competitor oligonucleotides on the left (X-axis). (D) As in C, except that the graph represents the relative band
intensities of the EMSAs from panel B.
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for the study of host cell TASHET-binding complexes.
To shed light on the identity of the cellular complexes
that recognize the TASHET in a TATA box dependent
fashion, we next performed a series of supershift experi-
ments using nuclear extracts from PBMC. Monoclonal
antibodies directed against human TATA-binding protein
(TBP) caused a significant loss of binding of the majority
of the TASHET-binding complexes (Figure 4A, lane 2 ver-
sus lane 1, see also Additional file 1 for quantification).We referred to the complexes that depend on one or more
general transcription factors for their formation as PICH-
1, PICH-2 and PICH-3, for pre-initiation complex of HIV
one through three (Figure 4). The addition of TFIIA anti-
bodies reproducibly caused a smearing and slower migra-
tion of PICH-2 (Figure 4, A, lane 3; see also Additional file
1, panel B), indicating that PICH-2 contains the basal Pol
II transcription factor TFIIA. The addition of antibodies
directed against TFIID subunits TAF5 and TAF10 to








































































































Figure 4 PICH formation from PBMC nuclear extracts depends
on general transcription factors. EMSAs were performed with
PBMC nuclear extracts as in Figure 2. (A) The indicated antibodies
were added to the reaction (lanes 2 to 6 and 8 to 11). Lanes 1 and 7
contain no antibody. Pre-initiation Complexes of HIV (PICHs), other
complexes and a non-specific complex are indicated by arrows at
the left. Black arrowheads highlight supershifted bands. Brackets
point out smearing of bands. White arrowheads highlight bands lost
upon antibody addition. (B) Quantification of EMSA band intensities
from panel A. Band intensities are expressed on the Y-axis as a
percentage relative to the strongest band in the control lane (panel
A lane 1 or 7) that was set at 100%. The graph on the left
corresponds to lanes 1 to 6, and the graph on the right to lanes 7
to 11. Band intensities that change by one third (33%) or more
relative to its level in the control lane (−) are highlighted in orange.
Complexes are displayed on the right (Z-axis), supershifting
antibodies on the left (X-axis). Shades of grey are used to distinguish
each PICH.
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wise, the addition of TAF6 antibodies caused a reduction
in PICH-1, PICH-2 and PICH-3 binding and was accom-
panied by a supershifted complex (Figure 4A, lane 5 ver-
sus lane 1). We concluded that PICH-1, PICH-2 and
PICH-3 are TFIID-dependent complexes. Antibodies
directed against TFII-I had a modest negative effect on
PICH-3 formation (Figure 4A, lane 10 versus lane 7), con-
sistent with a recent report that TFII-I can interact with
the HIV core promoter [42]. The addition of antibodies
against the mediator subunit, MED6 also reduced binding
of PICH-3 (Figure 4A, lane 11 versus lane 7), suggesting
PICH-3 depends on the mediator complex for its stable
association with TASHET. We also compared the effect ofsupershifts with TBP, TAF4, and TFIIA antibodies on
TASHET with cellular pre-initiation complexes that bind
the AdMLP. The results showed that all antibodies, espe-
cially anti-TFIIA, had a less dramatic effect on PIC bound
to the AdMLP (Additional file 2). The above described
supershift experiments show that the cellular PICH com-
plexes that recognize TASHET contain classical Pol II
basal transcription factors.
The presence of general Pol II transcription factors
within PICH cannot by itself account for TASHET's spe-
cific capacity to respond to Tat [16-21,37]. Given reports
that the E-box immediately downstream of the TATA
box may be important in the response to Tat [20], we
tested for the presence of two bHLH factors, AP4 [22]
and USF-1 [42], that have been reported to bind to
this E-box. Antibodies directed against AP4 resulted
in the loss of a minor TASHET-interacting complex
(Figure 4A, lane 9 versus lane 7 see also Additional file
1, panel B), in agreement with previous findings of AP4
interacting with the 3’ E-box [22]. The addition of USF-
1 antibodies resulted in the loss of a complex that binds
specifically to the TASHET (Figure 4A, lane 8 versus
lane 7). Thus PBMC nuclear extracts contain the bHLH
factors USF-1 and AP4 both of which are able to bind to
TASHET in EMSA.
We next tested whether PICH-1, -2, -3, USF-1 and
AP4 from HeLa cell nuclear extracts also bound to
TASHET using EMSA and supershift assays. As was the
case of PBMC nuclear factors, antibodies against TBP
reduced binding of all three PICH (Figure 5A, lane 2
versus lane 1). TFIIA antibodies also caused a similar
change in PICH-2 mobility in HeLa and PBMC extracts
(Figure 5 A, lane 3; see also Additional file 1, panel D).
Indeed, in all cases supershift experiments with TFIID
subunits, USF-1 and AP4 antibodies showed comparable
effects on PBMC and HeLa nuclear complexes binding
to TASHET (Figures 4 versus 5 and Additional file 1).
The above results together reveal the existence of PICH
from both HeLa cells and PBMC, distinct from canon-
ical PIC, that specifically recognizes the TASHET.
E-box binding factor USF-1 is dispensable for Tat
trans-activation
A previous mutational analysis suggested that the E-box
immediately downstream of the HIV TATA box may be
important for the response to Tat, potentially via binding
of the bHLH factor AP4 [20]. A more recent study
showed that AP4 is not required for Tat trans-activation
[22]. To dissect in further depth the role of the 3’ E-box
(Figure 6A) in the response to Tat, we designed point
mutations predicted to either improve or abolish the
binding of USF-1, since it represents the predominant E-
box binding factor in nuclear extracts (Figures 4A and







































































































Figure 5 PICH formation from HeLa nuclear extracts depends
on general transcription factors. As in Figure 4, except that EMSAs
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Figure 6 USF-1 binds HIV core promoter but is dispensable for
Tat trans-activation. (A) Mutations in TASHET used in EMSA and
transient transfections shown in B, C and D: the name of the
mutation is indicated at the left of the sequence. The mutated
nucleotides are indicated in white. The TATA box is delimitated by a
purple box and the E-box by a green box: the lighter green region
indicates nucleotides not forming part of the core E-box consensus
sequence. (B) EMSAs were performed as in Figure 2. The different
radiolabelled HIV promoter mutations used as a probe are indicated
at the bottom of the figure. Supershift experiments were performed
with the indicated antibodies. PICHs are indicated by an arrow at
the left of each panel. An X in red indicates PICHs whose formation
is severely impaired by the mutations. (C) HeLa cells have been co-
transfected with a plasmid expressing the Renilla luciferase under
the control of HIV wt or mutated promoter with or without a Tat
expression plasmid as indicated under the X-axis. Luciferase activity
was measured 48 h after transfection in cell extracts. Basal (−) and
Tat-induced (+) activities are displayed. Mutation in the TATA box is
shown in purple, mutations in the E-box are indicated in green.
(D) As in C except that results are expressed as Tat trans-activation,
obtained by the ratio of RLU in presence of Tat versus without Tat.
Values are expressed as a percentage of wt HIV promoter luciferase
activity (100%).
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CACGTG E-box (Figure 6A, “USF-1+”), with increased
affinity for USF-1 with respect to the wild type HIV E-
box, CAGCTG. BLAST searches showed that the
CACGTG E-box is extremely rare in natural HIV strains
presumably because it is under negative selection pres-
sure in HIV infected individuals. A second mutation was
designed to prevent USF-1 binding but expected to re-
tain replicative capacity based on sequence conservation
(Figure 1C). Two nucleotide changes that exist individu-
ally in natural HIV isolates were introduced to produce
a CGGCCG sequence (Figure 6A, “USFKO”) that is not
expected to bind USF-1 [44]. These point mutations
were tested for USF-1 binding with HeLa cell nuclear
extracts. TASHET lacking a TATA box was used as a
negative control and displayed virtually no PICH or
USF-1 binding (Figure 6B, lanes 4–6). To confirm the
identity of PICHs, TBP antibodies were used in super-
shift analysis as a positive control (Figure 6B, lanes 2, 5,
9 and 11). The CACGTG (USF-1+) E-box bound more
strongly to USF-1 (Figure 6B, lane 7 versus lane 1). The
identity of USF-1 was confirmed by supershift analysis
(Figure 6B, lane 8 versus lane 7). The CGGCCG
(USFKO) sequence bound to PICH-3, PICH-2 and
PICH-1 but, importantly, bound no USF-1 (Figure 6B,
lane 10 versus lane 1). The increased affinity of the USF-1+ mutation for USF-1, as well as the lack of binding of
the USFKO mutation to USF-1, was further reinforced
using competition assays in EMSA (Additional file 3).
To test the impact of these mutations on Tat trans-acti-
vation in living cells, we introduced them into HIV pro-
moters driving Renilla luciferase as a reporter gene. As
expected a construct lacking a functional TATA box did
not respond to Tat co-transfection in HeLa cells
Figure 7 CTGC DNA motifs are essential for the stable
formation of PICH-1, -2 and −3 on TASHET in vitro. EMSAs were
performed as detailed in Figure 2. (A) Mutations used in EMSA and
transient transfections shown in Figures 7 and 8: The name of the
mutation is indicated at the left of the sequence. The mutated
nucleotides are indicated in white. The purple box indicates the
TATA box. The blue boxes indicate the CTGC motifs: the CTGC5’
motif is located just upstream of the TATA box, and two CTGC3’
motifs are located just downstream of the TATA box, the first one in
the reverse orientation, the second one in the forward orientation.
The mutations are named after the displayed mutations. (B) The
indicated unlabelled competitors were added to the reaction (lanes
2 to 5). Lane 1 contains no competitor. (C) Relative intensity of the
different complexes was calculated by phosphorimager analysis of
the EMSA shown in B. Results are expressed relative to the intensity
observed without competitor that was set to 1 for each complex.
Wilhelm et al. Retrovirology 2012, 9:62 Page 8 of 19
http://www.retrovirology.com/content/9/1/62(Figure 6C and 6D, TATAKO). The USF+ mutation
decreased the Tat response by approximately two-fold,
showing that increased USF-1 binding did not enhance
Tat activation. Importantly, the USF-1KO mutation that
did not bind USF-1 resulted in wild type levels of Tat
trans-activation in living cells. These results show that
USF-1 binding to TASHET is not required for Tat
responsiveness.
CTGC DNA motifs are required for correct PICH formation
in vitro and Tat trans-activation in living cells
Since the above mutational analysis showed that neither
USF-1 binding nor an intact E-box was required for Tat-
responsive transcription, we next asked what cis-acting
DNA sequences within TASHET are essential to respond
to Tat. Building upon previous mutational studies [18-
20,45], in addition to natural TASHET conservation
(Figure 1C), we have performed an extensive mutational
analysis of TASHET sequences flanking the HIV TATA
box (unpublished results). For simplicity, here, we
present a selective subset of the most informative muta-
tions focusing on the three CTGC motifs that flank the
HIV TATA box (Figure 7A). Since previously reported
individual point mutations within these motifs showed
no effect on Tat trans-activation [45], we postulated that
mutations to more than one CTGC motif may be
required to reveal their impact. We mutated the cytosine
at position one and the guanine at position three of the
CTGC motifs (Figure 7A) as these are highly conserved
in natural HIV isolates (Figure 1C). To test the impact
of mutating the conserved CTGC motifs on PICH for-
mation in EMSA, we challenged PICH bound to wild
type TASHET with unlabelled competitors bearing these
point mutations within the CTGC motifs (Figure 7B and
7C; see also Additional file 4A for numeric quantifica-
tion). Mutation of the 5’ CTGC motif only slightly
decreased affinity of PICHs for TASHET since it com-
peted nearly as well as wt competitor for PICH
(Figure 7B lane 2 versus lane 5). Mutation of the two 3’
CTGC motifs decreased the affinity of PICH-2 and
PICH-3 and USF-1 for TASHET, leading to a weaker
competition (Figure 7B, lane 3). Finally, the combination
of mutation in the 5’ and the two 3’ CTGC motifs
resulted in a strong reduction in the affinity of PICHs
for TASHET (Figure 7B, lane 4). We next radiolabelled
TASHET DNA bearing point mutations in all three
CTGC motifs for use in EMSA with HeLa cell nuclear
extracts. The mobility and intensity of the resulting
complexes were remarkably distinct from those forming
on the wild type TASHET (Figure 8A, lane 2 versus lane
1). We refer to these aberrant complexes collectively as
aPIC (Figure 8A and 8B) to indicate that they do not
allow Tat-responsive transcription (see below). To probe
the constituents of these altered aPIC, we again usedsupershift analysis. We found no complexes to be
affected by TFIIA antibodies (Figure 8B, lane 2). Import-
antly, these aberrant complexes were inhibited by the
addition of antibodies raised against classical PIC subu-
nits like TBP and MED6 (Figure 8B, lane 5 and lane 6;
see also Additional file 4B for quantification). The lowest
mobility complex was also supershifted by antibodies
against TFIID subunits TAF10 and TAF6 (Figure 8B,
lane 7 and lane 8). The formation of the major aPIC
complex was slightly but reproducibly, reduced by the











































































































Tat- + - + - + - +
Figure 8 CTGC motifs flanking the HIV TATA box are required
for correct PICH formation in vitro and Tat trans-activation in
living cells. EMSAs were performed as in Figure 2. (A) EMSA
mobility comparison of complexes formed on HIVwt promoter (lane
1) and CTGC5’3’ mutant (lane 2). PICHs bound to HIVwt are
indicated at the left of the panel. Complexes formed on CTGC3’5’
mutant are indicated at the right as aberrant pre-initiation
complexes (aPIC) (B) For supershift assay with the CTGC5’3’
radiolabelled probe, no antibody (lanes 1 and 9) or the indicated
antibodies (lanes 2–8 and 10–11) were added in the reaction.
Arrowheads indicate supershifted bands. (C) Basal and Tat
transactivated promoter activity and (D) Tat transactivation are
measured by luciferase activity in extracts of HeLa cells as in
Figure 6C and D. Mutations in the CTGC motifs are shown in shades
of blue.
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TASHET bearing mutated CTGC motifs contained no
USF-1 (Figure 8B, lane 11). This result is expected since
the E-box embedded within the 3’ CTGC motifs is
destroyed by these point mutations (Figure 7A and
Figure 6A). In contrast AP4 antibodies resulted in a
strong supershift of the major complex binding TASHET
with mutated CTGC motifs (Figure 8B, lane 10 versus
lane 9). Together, these observations indicate that the
CTGC motifs flanking the HIV TATA box are required
for correct PICH formation. Furthermore, the mutation
of these flanking CTGC motifs results in aberrant com-
plexes that retain at least some of the classical PIC com-
ponents plus the transcription factor AP4.
To test the effects of the mutations that altered PICH
formation in vitro on Tat trans-activation in living cells,
we again employed co-transfection of reporter constructs
carrying the full length HIV LTR driving luciferase with aTat expression vector in HeLa cells. Co-transfection of a
construct bearing point mutations within the single 5’
CTGC increased basal HIV LTR-directed transcription
(Figure 8C, mutation CTGC5’) without significantly in-
creasing Tat trans-activation (Figure 8D). This result
mirrors the previously reported effects of mutations im-
mediately 5' of the TATA box [46]. Mutation of the two 3’
CTGC motifs resulted in a significant drop in Tat trans-
activation (Figure 8D, mutation CTGC3’) without signifi-
cantly changing basal transcription (Figure 8C). A con-
struct bearing mutations in all three flanking CTGC
motifs resulted in highly impaired Tat trans-activation
(Figure 8D, mutation CTGC5’3’), yet only slightly
decreased basal HIV LTR-driven transcription (Figure 8C).
To rule out indirect effects on Tat trans-activation by
grossly altered transcriptional start sites, the start
sites of transcription for mutated core promoters were
analyzed by primer extension in transfected HeLa cells.
The major start site of transcription was found to be un-
changed with all mutations used (Additional file 5). We
concluded that the CTGC DNA motifs flanking the TATA
box are essential for Tat trans-activation of the HIV
promoter.
CTGC DNA motifs within TASHET are essential for HIV
gene expression in single-round infection assays
To further test the importance of the CTGC motifs
flanking the HIV TATA box in a physiologically relevant
context, we next employed previously described single
round infection assays [47,48]. We used pseudotyped
viral particles to infect PBMC from healthy donors as
shown schematically in Figure 9A. This system relies on
a luciferase reporter gene that replaces the HIV nef gene
with the VSV-G envelope protein provided by co-
transfection of packaging cells. The advantages of this
system are three fold. Firstly, primary PBMC are used
and represent the major physiological targets for natural
HIV infection. Secondly, the HIV promoter is integrated
in a single copy into the chromatin context as in a nat-
ural infection. Thirdly, Tat expression is driven by the
proviral HIV promoter and is therefore supplied in an
amplification loop identical to a natural infection.
To define the impact of TASHET point mutations on
proviral HIV transcription in PBMCs, we isolated the
cells and activated them with mitogens IL-2 and PHA
before infection with viral particles bearing point muta-
tions in the 3’ LTR that are subsequently copied into the
5’ LTR by HIV reverse transcriptase before integration
into the host cell genome (Figure 9A). Luciferase activity
was measured to monitor HIV gene expression forty-
eight hours post infection. An HIV genome with a
mutated TATA box served as a negative control and
resulted in very low levels of luciferase activity




























































Figure 9 The CTGC motifs of TASHET are essential for activated HIV transcription in single-round infection assays. (A) Mutations have
been introduced into the 3’LTR of pNL4-3-LucE- (in red). Viral proteins whose expression is deficient in this construct are shown in grey (env, nef).
The mutated pNL4-3-LucE- constructs were co-transfected together with a plasmid expressing VSV-G envelope into HEK293 packaging cells for
virion production. Culture supernatant was titrated for viral content by ELISA p24-antigen titration to normalize the quantity of virus for PBMC
infection. Activated PBMCs were infected, allowing genomic integration of the virus. Luciferase expression corresponding to retroviral promoter
activity was measured 48 h later. (B) RLU were measured and normalized to proviral content as measured by qPCR of an LTR sequence in
infected cells extract. Results were expressed as a percentage of wt HIV luciferase activity.
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approximately 70% of wild type levels (Figure 9B, USF+).
Point mutations that prevent USF-1 binding but retain
PICH-2 binding (Figure 6) resulted in Tat-activated HIV
gene expression that was measurably higher than that of
wild type promoter (Figure 9B, USF1KO). We conclude
that in the single round infection assay in PBMC USF-1
binding is not essential for activated HIV gene expres-
sion. Mutation of the 5’ CTGC motif alone had little ef-
fect on HIV gene expression and even slightly increased
luciferase activity in infected PBMC (Figure 9B,
CTGC5’). Mutations within the two 3’ CTGC motifs
reduced HIV gene expression by approximately one half
(Figure 9B, CTGC3’). Importantly, the point mutation ofthe three flanking CTGC motifs reduced HIV expression
levels strongly showing that, in the proviral chromatin
context and in primary PBMC, these motifs are essential
for activated HIV gene expression.
TAR RNA prevents stable PICH-2 binding to TASHET DNA
Given that the CTGC motifs of TASHET are required
for Tat responsive transcription, and recent observations
that TAR RNA can displace complexes formed on the
HIV promoter [11], we next asked whether TAR has an
impact on the formation of the specialized PIC (PICH)
that recognize TASHET. TAR RNA and mutations
thereof (Figure 10A) were transcribed in vitro, purified
and then added to EMSA with radiolabelled TASHET
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of PICH-2 (Figure 10B, lane 2 versus lane 1). To deter-
mine the sequences of TAR required to prevent PICH-
2’s stable binding to TASHET, we employed mutations
in the loop and bulge region of TAR previously shown
to prevent Tat trans-activation [49-51]. TAR RNA
with mutated loop sequence, like the wild type, was
able to prevent stable PICH-2 – TASHET interaction
(Figure 10B, lane 3 versus lane 2). In contrast TAR RNA
lacking the three nucleotide bulge known to bind Tat
was significantly less able to prevent PICH-2 – TASHET
interaction (Figure 10B, lane 4 versus lane 2). Mutation
of the bulge and loop sequences together nearly abol-































































































Figure 10 TAR RNA prevents stable PICH-2 binding to TASHET
DNA. (A) The stem loop structure of TAR RNA mutants is depicted
(nt 1 to 83) with the name of the mutation above. Mutations in the
loop and/or in the bulge are shown in red. The red dots stand for
nucleotides deletions. (B) 40 fold molar excess of indicated TAR
mutant in vitro transcripts have been added in EMSA reactions that
were performed as detailed in Figure 2. (C) PICH-2 intensity has
been quantified by band density measurement on EMSA
autoradiography. Results are expressed relative to PICH-2 intensity in
the control lane 1 containing no TAR that was set to one (−).(Figure 10B, lane 5). Changing the nucleotide sequence
of the bulge from UCU to AAG only slightly reduced
the ability of TAR to destabilize the PICH-2 – TASHET
interaction (Figure 10, lane 6). We concluded that the
structure of the bulge of TAR is more critical than its
nucleotide sequence for the destabilization of PICH-2 –
TASHET binding. This conclusion is further supported
by the single nucleotide change at cytosine 23 that did
not alter TAR’s impact on PICH-2 – TASHET interac-
tions (Figure 10B, lane 7). The impact of TAR on PICH-
2 – TASHET interaction was quantified and is shown in
Figure 10C. To test the specificity of TARs on the
PICH-2 complex, we also tested their impact on the
interaction of canonical PIC with the AdMLP promoter
and found no effect on any complexes (Additional file
6). Furthermore, the complexes binding to the CTGC5’3’
TASHET mutation that no longer responded to Tat were
not affected by the presence of TAR RNA (Additional
file 6). TAR RNA has recently been shown to displace a
7SK snRNP from the HIV promoter [11] raising the pos-
sibility that PICHs at the HIV core promoter could con-
tain 7SK RNA. To test this possibility we used RNase H-
directed degradation of 7SK in HeLa cell nuclear
extracts. Efficient 7SK degradation had no significant ef-
fect on PICH formation in EMSA, showing that 7SK is
not an integral component of PICHs (Additional file 7).
Together these results show that TAR RNA, via its bulge
sequence, can prevent stable binding of PICH-2 to
TASHET DNA.
Discussion
The data we present here show for the first time that the
TATA box of HIV and adjacent sequences of HIV essen-
tial for Tat trans activation (TASHET) is recognized by
cellular pre-initiation complexes (PICHs) that: 1) are dis-
tinct from canonical PIC that recognize the model
AdMLP, 2) require the flanking CTGC motifs for their
accurate formation, and 3) include PICH-2 whose stable
binding to TASHET is disrupted by HIV TAR RNA.
TASHET has been shown to play a pivotal role in gov-
erning Tat-activated HIV transcription in cell culture
[16-21,37] and by logical extension is thought to impact
the dynamics of latency in vivo [52]. Moreover, previous
studies have provided a proof-of-principle that DNA
sequences within the TASHET element of the HIV core
promoter can be specifically targeted by polyamides to
modulate HIV transcription [29,53,54]. The host cell
PICH complexes identified here are of importance as an
essential step in the activation of HIV transcription, and
also as a source of potential new drug targets for the
eradication of HIV from infected individuals.
The functional diversity of core promoters and of the
transcription factors that they bind is increasingly recog-
nized as an important contributor to genomic regulation
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ments (DPE, DCE, BRE, XCPE1, etc.), the HIV promoter
contains only an identified TATA box [25] and a non-
classical initiator (Inr) element [55]. In contrast to
TASHET [16-21], the HIV Inr can be replaced by a
heterologous AdMLP Inr for Tat-responsive transcrip-
tion [56]. The data presented here excluded an essential
role for USF-1 binding to the 3' E box in Tat trans-acti-
vation (Figure 6). Two other CTGC motifs were found
in upstream HIV LTR motifs termed RBEIV and RBEIII
elements [57], but were not required for Tat trans-acti-
vation [58]. The 3’ CANNTG E-box is embedded within
the 3’ palindromic GCAGCTGC motif (Figure 6A). The
3’ E-box displays relatively low sequence conservation
[22,39] (Figure 1C). Our data could help explain why a
GCAGCCGC variant is frequently found in natural HIV
isolates (Figure 1C), yet weakens the consensus E-box
GCAGCTGC, if positive selection pressure to maintain
PICH-2 - CTGC contacts can prevail over selection to
maintain USF-1/AP4 - E-box interactions in HIV
infected individuals.
We postulate two mechanisms to account for the spe-
cific functional and DNA binding properties displayed
by the PICH described herein. First, the known Pol II
general transcription factors (GTFs) could have unique
affinities or conformations when bound to TASHET that
confer functional specificity. There are precedents for
core promoter specific GTF function, for example
TFIIA, that we have found as a component of PICH-2,
has been shown to have positive or negative effects on
transcription depending on the core promoter sequence
[59]. A second alternative is that unknown accessory
(non-GTF) host cell proteins could bind to TASHET to
confer Tat-responsiveness. The two possible mechanisms
are not mutually exclusive and could contribute together
to PICH specificity. Certain TBP-associated factors
(TAFs) can recognize core promoter elements [32,60].
Our supershift analysis suggests that stable PICH forma-
tion on TASHET requires at least some core TAFs. The
PICH appear to bind less tightly to TASHET compared
to canonical PIC to the AdMLP, since antibodies to
TFIID subunits disrupt PICH – TASHET interactions
more readily than PIC – AdMLP interactions in EMSA
(Additional file 1). These results are compatible with
chromatin immunoprecipitation (ChIP) results obtained
from Tat-expressing cells showing that TAF occupancy
of the HIV core promoter is lower than that of TBP
when compared to an adenovirus E1b core promoter
[61]. Nevertheless, both TFIID [62] and TAFs [63] have
been shown to bind the HIV core promoter in vitro. The
ratios of TBP/TFIID occupancy measured by ChIP must
be interpreted in light of the fact that association of TBP
with TFIID is highly dynamic both in vitro [64] and in
living cells on model promoters [65].Cellular complexes have been previously reported to
bind TASHET [37,57,66], but their identity has remained
enigmatic due to their enormous size, subunit complex-
ity, and their dynamic nature on core promoters. The
minimal set of classical GTFs required for PIC formation
and transcription is considered to be 70 polypeptides
[67], and proteomic studies of yeast PIC composition
imply that hundreds of proteins are involved [68].
TASHET’s key role in HIV transcription was discovered
more than two decades ago [16], yet the complexes rec-
ognizing it have remained out of reach. Based on the
GTFs they contain, PICH-1 (e.g. TBP, TAFs), PICH-2
(TBP, TAFs, TFIIA) and PICH-3 (TBP, TAFs, Pol II)
likely correspond to intermediates in the PIC assembly
pathway [69]. The availability of a tractable EMSA to de-
tect PICH, the demonstration that PICH contain
classical GTFs yet are distinct from canonical PIC, to-
gether with the definition of the nucleotides essential
for their formation, opens the door for molecular
genetic, biochemical and proteomic dissection of PICH
composition.
By revealing that PICH formed on the HIV core pro-
moter are distinct in electrophoretic mobility and DNA
binding specificity from PIC that bind the prototypical
AdMLP, our data provide a mechanistic explanation for
the specific requirement of TASHET in Tat trans-activa-
tion. Physical interactions between HIV Tat and Pol II
PIC components including TBP [27,28] and TFIIB
[70,71] have been previously reported. Furthermore, re-
combinant Tat was shown to enhance the sarkosyl-
resistance of purified TFIID – TFIIA complexes on HIV
TATA box region in EMSA in vitro [26]. To date we
have observed no significant effect of recombinant Tat
on endogenous PICH behaviour in EMSA. One reason
that could explain a lack of interaction between Tat and
the PICHs is that the TASHET DNA employed in our
EMSAs lacks the SP1 sites that are essential for recruit-
ment of 7SK snRNP [11] that can interact with Tat [72].
Tat’s capacity to enhance transcription elongation rates
via P-TEFb is well established [15], however in several
experimental settings Tat can also positively influence
transcription initiation [73]. Our analysis did not distin-
guish between the relative contributions of enhanced
elongation versus enhanced initiation. Instead, the dem-
onstration that TAR RNA can influence PICH-2 binding
to TASHET reinforces and extends recently proposed
models [11,74] for Tat function in which the initiation
and elongation steps of transcription are mechanistically
coupled (Figure 11A).
Our data show that TAR RNA, via its bulge structure,
can prevent stable association of PICH-2 with TASHET
in EMSA (Figure 10). In principle TAR could act by
blocking association of PICH-2 with TASHET or by ac-












Figure 11 A hypothetic model for PICH function in Tat trans-activation. (A) A highly simplified schema illustrating the coupling of pre-
initiation complex (PIC) dynamics with transcriptional elongation. On the wild type HIV core promoter nascent TAR RNA contacts PICH to increase
the rate of dissociation of PICH-2 (upward green arrow), thereby increasing the rates of the subsequent cycle of PICH formation and potentially
Pol II escape. (B) In contrast, on core promoters lacking functional CTGC motifs, aberrant complexes (aPIC), containing AP4, are slow to dissociate
(upward red arrow) and TAR has no impact on them (see text for details).
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TASHET because PICH-2 binding correlates positively
with Tat-responsiveness (Figure 6, and data not shown),
and because TAR decoys do not inhibit PIC formation
in vitro [75]. We propose a dynamic model in which cel-
lular PICH specifically recognize TASHET via its CTGC
motifs. Nascent TAR transcribed by Pol II facilitates the
departure of PICH-2, in turn accelerating the next cycle
of PIC formation (Figure 11B). This model is compatible
with the model recently proposed by D’Orso et al. in-
cluding the expulsion of 7SK snRNP from the HIV pro-
moter by TAR [11]. A dynamic model is also compatible
with the observation that point mutations to the CTGC
motifs result in aberrant but stable aPIC formation and
a failure to respond to Tat (Figure 8). The presence of
AP4 in aPIC was unexpected since the 3’ E-box is
destroyed by these mutations. A plausible explanation is
that AP4 may be recruited into non-productive PICH
via protein-protein interactions. The dynamic model we
propose for the impact of both PICH association anddisassociation on Tat trans-activation is consistent with
previous genetic observations that appropriate PIC
destabilization is necessary for activated transcription in
yeast [76] and recent reports showing that transcription
factor dynamics are important in transcriptional regula-
tion [77,78].
Our results shed new light on the mechanisms that con-
trol HIV gene expression, but also have broader implica-
tions for the combinatorial control of cellular gene
expression. Biologically, the sequence of core promoters
has been shown to dictate: 1) the differential response to
activators [79], 2) the response to cell-type specific enhan-
cers [80], and 3) the alternative splicing of the transcribed
pre-mRNA [81]. The composition of core promoter-
binding complexes is increasingly recognized as being very
heterogeneous [31-33,82]. In addition, the range of core
promoter cis-acting DNA sequences is also known to be
highly complex [6,60]. To our knowledge, to date no bio-
chemical data had been reported showing that distinct
core promoters bind PIC that are functionally distinct, yet
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II. The data presented here link a specific biological out-
come (Tat trans-activation), to a core promoter sequence
(the CTGC motifs) and also to a specialized core
promoter-binding complex (PICH-2). The broader mech-
anistic implication is that core promoter complexes, des-
pite the fact that they contain common classical GTFs,
can confer very distinct transcriptional responses.
Conclusions
The regulation of HIV transcription dictates viral latency
versus active replication. The viral Tat trans-activating
protein is essential for activated HIV transcription. A
long-standing unanswered question concerning the
mechanism of Tat trans-activation is: why can the HIV
core promoter TATA box region (TASHET) not be func-
tionally replaced by heterologous TATA elements? We
report here that CTGC DNA motifs in the HIV core
promoter are essential for the formation of specialized
Tat-responsive pre-initiation complexes (PICH). PICH-2
contains the general transcription factor TFIIA and its
stable association with TASHET is prevented by the
presence of HIV TAR RNA. The detection of Tat-
responsive PICH binding complexes provides an essen-
tial step forward towards the full elucidation of the
mechanisms underlying activated HIV transcription, and
paves the way for the identification of new molecular
targets for therapies to eradicate latent HIV.
Methods
Antibodies
Antibodies used in this study were raised against: AP-4
(sc-18593), Med6 (sc-9434), TFIIA-γ (sc-5316), USF-1
(sc-229), all from Santa Cruz, CA; Pol II (8WG16) from
Covance (Emeryville, CA); SMARCA3 (BL825) from
Bethyl Laboratories (Montgomery, TX); TFII-I (#4562)
from Cell Signaling (Beverly, MA). Monoclonal anti-
bodies against TFIID subunits were generous gifts from
Dr. Laszlo Tora and have been described [83-85] : TBP :
TBP-1 (2 C1), TBP-2 (4 C2), TBP-3 (3 G3) ; TAF4
(20TA) ; TAF5 (1TA) ; TAF6 (25TA) ; TAF10 (2B11) ;
TAF15 (2B10).
Plasmids
pCMV-Tat has been described [86]. To obtain the nega-
tive control lacking Tat coding sequence, pCMV-Tat was
linearized with XhoI and SalI restriction enzymes and
blunted with the Klenow enzyme before religation.
pHIV-RL is based on the pHRL-null vector (Promega
#E6231) whose XbaI and SphI sites were eliminated by
restriction enzymes, Klenow digestion and religation.
The HIV-1 LTR of pU3S [57], derived from pHIVSCAT
[18], was cloned into the XhoI and HindIII sites of the
previously modified pHRL-null. The resulting plasmidwas digested with XhoI and KpnI and treated with Kle-
now enzyme before religation to eliminate the 5' XbaI
site of the LTR. All the Renilla luciferase mutant con-
structs were based on pHIV-RL, by replacing the wild-
type core promoter sequence between the XbaI and SphI
sites with 35 bp synthetic oligonucleotides bearing the
various mutations. Key mutations have been cloned in
pNL4-3-LucE- (kindly provided by Michel J. Tremblay,
Université Laval, Québec) for pseudotyped virus produc-
tion. To facilitate the mutation, the XhoI-NcoI portion
of pNL4-3-LucE- has been cloned into phRLnull and
directed mutagenesis was performed by PCR as previ-
ously described [87]. The XhoI-NcoI portion was then
reintroduced into pNL4-3-LucE- by standard subclon-
ing. The envelope encoding plasmid pCMV-VSV-G was
also a gift of Dr. M.J. Tremblay. Mutated TAR RNAs
based on previously reported mutations [49-51] were
cloned into the SphI and SacI sites of the pHIV-RL
backbone using synthetic oligonucleotides bearing muta-
tions. In the ΔTAR mutant, 30 nucleotides were deleted
in TAR sequence by SacI-HindIII digestion, Klenow
blunting and religation.
Cell culture and nuclear extracts
HeLa cells (ATCC # CCL-2) were grown in DMEM sup-
plemented with 2.5% FBS and 2.5% NBCS (Wisent).
HEK293 cells (ATCC #CRL-1573) were grown in DMEM
containing 10% FBS. Peripheral blood mononuclear cells
(PBMC) were isolated from healthy donors by lymphocyte
separation medium (Wisent) according to manufacturer’s
instructions and stimulated 3 days with PHA-L (1 μg/ml,
L2769 Sigma) and IL-2 (30 U/ml, Sigma or F081 Bioshop)
before viral infection or nuclear extracts preparation. Nu-
clei were prepared from activated PBMC [88] and HeLa
cells [89] as previously described. PBMC and HeLa cell
nuclei were then used to prepare nuclear extracts accord-
ing to the protocol of Dignam et al. [89].
In vitro transcription
To generate TAR transcripts, the sequence was first amp-
lified by PCR using a sense primer containing a T3-
polymerase recognition site. Three 50 μl reactions were
prepared, each containing 200 ng of matrix plasmid,
1 mM of each dNTPs, 400 nM of sense and reverse pri-
mer, 2.5 U of Pfu turbo enzyme in 1x reaction buffer
(NEB, Ipswich MA). PCR products were pooled and puri-
fied by phenol-chloroform extraction and ethanol precipi-
tation. The obtained template was reverse transcribed for
1 to 2 h at 37 °C in a mix containing 0.5 mM of each
rATP, rCTP and rUTP, 0.1 mM rGTP, 0.2 mM Cap ana-
log, 12.5 pmol (10 μCi) of α-32P UTP, 2 μl RNA guard,
34U of T3 RNA-polymerase in 100 μl of 1X transcription
buffer (40 mM Tris–HCl pH7.9, 6 mM MgCl2, 2 mM
spermidine, 10 mM DTT). The transcription product was
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nol blue and xylene cyanole, 10 mM EDTA in deionized
formamide), boiled for 90 seconds and immediately
chilled on ice, then loaded on a pre-equilibrated denatur-
ing 8 M urea- 4.75% polyacrylamide gel in TBE 1X and
run for 45 min at 300 V. Full length TAR transcripts were
identified by autoradiography and then excised from the
gel for extraction with 300 μl crunch solution (300 mM
Na Acetate, 0.2% SDS) on a rocking table twice for
20 min. Pooled supernatants were phenol-chloroform
extracted twice, ethanol precipitated, resuspended in
water and the radioactive counts were measured for the
calculation of RNA concentration.
Electrophoretic mobility shift assay (EMSA)
The specific EMSA protocol used in this study has been
described in detail [36]. Briefly, 20 μg nuclear extracts
were mixed together with 4μg of acetylated BSA (Pro-
mega #R3961), 2 μg of Poly(dI-dC)•Poly(dI-dC) (Sigma)
and 1.8pmol of nonspecific double-stranded oligo-
nucleotide (sense : GATCCGGAGTACTTCAAGAACG;
reverse : GATCCGTTCTTGAAGTACTCCG) in a final
volume of 20 μl of binding buffer (20 mM Hepes, 5 mM
MgCl2, 8% glycerol, 100 mM KCl), for 5 minutes on ice.
For competition assays, TAR RNA or 200pmol (unless
otherwise specified) of unlabelled competitor oligo-
nucleotide were added to the reaction. 1pmol of labelled
doubled-stranded promoter (35 bp) were added to reac-
tion for 15 minutes at room temperature. For supershift
assays, 1 to 4 μl of specific antibody were added to the
sample, and the reaction was continued on ice for 1 add-
itional hour. Samples were then loaded on a native 4.5%
polyacrylamide gel and complexes separated for 3.5
hours at 150 Volts. For RNase H directed degradation of
7SK RNA within the nuclear extracts used in EMSA, nu-
clear extracts were first incubated with anti-sense oligo-
nucleotide and 10 U of RNase H (NEB) for 1 h at 30°C
in binding buffer. The remaining constituents were then
added as indicated above (BSA, Poly(dI-dC)•Poly(dI-dC),
non specific oligonucleotide and finally radiolabelled
oligonucleotide) and the reaction was allowed to con-
tinue as described above. The anti-sense oligonucleo-
tides for 7SK RNase H directed digestion have been
described [90].
RT-PCR on EMSA samples
To check for proper and specific RNA degradation, the
EMSA reaction was doubled, and RNAs were recovered
from one half of the resulting volume by trizol extraction.
The samples were DNase I treated (Promega) for 30 min
at 37°C. RNAs were reverse transcribed by MMuLV-RT
(Roche) using random hexamer-primers according to
manufacturer’s recommendations. PCR was performed on
1/10 of the obtained cDNA to amplify 7SK-snRNA :forward GGATGTGAGGCGATCTGGC ; reverse :
AAAAGAAAGGCAGACTGCCAC; or U6snRNA : for-
ward CTCGCTTCGGCAGCACATATAC ; reverse
GGAACGCTTCACGAATTTGCGTG.
Transfection and luciferase assay
For Renilla Luciferase reporter assays, HeLa cells were
transfected in 96 well plates with DMRIE-C (Invitrogen,)
according to the manufacturer’s recommendations.
12000 cells were seeded into 96 well plates the day before
transfection in complete medium. 50 ng of pHIV-RL
construct, together with 15 ng of either pCMV-Tat or the
empty control vector were transfected, complexed with
0.2 μl of DMRIE-C transfection reagent in a final volume
of 100 μl of OptiMEM (Invitrogen). Two days later, the
Renilla Luciferase assay system (# E2810, Promega,
Madison, WI) was used according to the manufacturer’s
instructions to lyse and measure luminescence on an
automated luminometer (BMG Labtech, Ortenberg,
Germany).
Primer extension
HeLa cells were transfected in 6 well plates with DMRIE-
C (Invitrogen,) according to the manufacturer’s recom-
mendations. 5 X 105 cells were seeded per well the day be-
fore transfection in complete medium. 1.25 μg of pHIV-
RL construct, together with 250 ng of either pCMV-Tat or
the empty control vector were transfected, complexed
with 4 μl of DMRIE-C transfection reagent in a final vol-
ume of 1.5 ml OptiMEM (Invitrogen). RNAs were
extracted with Trizol (Invitrogen) reagent after 24 h. 5 μg
of total RNA was used in primer extension reactions for
1 h at 42 °C in a buffer containing 1.25 mM Tris pH 8.0,
1.75 mM KCl, 5 mM DTT, 10 mM MgCl2, 125 μM of
each dNTP, 25 μg/ml Actinomycin D, 5U of AMV
Reverse-Transcriptase (Roche) and 20 ng of a PNK radi-
olabelled reverse primer specific for TAR (5’ GCTTTAT
TGAGGCTTAAGCAGTG3’). The ethanol precipitated
pellet was resuspended in formamide dye, boiled and
loaded on an 8 M urea 9% polyacrylamide denaturing se-
quencing gel.
Virus production
The day before transfection, 4 X 106 HEK-293 packaging
cells were seeded on 100 mm dishes in 9 ml complete
medium. Calcium phosphate transfection was performed
by mixing together 1.5 μg pVSV-G and 13.5 μg pNL4-3-
LucE- based constructs in 500 μl of 250 mM CaCl2 and
500 μl HBS 2X (280 mM NaCl, 50 mM Hepes, 1.5 mM
Na2HPO4, pH7.08). The precipitates were allowed to form
for 2 minutes and immediately added drop-wise on top of
cell culture medium. Two days later, the virion containing
medium was recovered and filtered through a 0.45 μm fil-
ter and kept frozen at −80°C. Virion content was
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ent assay (ELISA) for the viral major core protein p24 that
has been previously described [47].
Viral reporter assays
PBMC were activated for 3 days before infection. 106 cells
were directly resuspended in the minimal volume of
complete medium and virus stock to add 100 ng of p24
per 106 cells. Pre-infection was allowed to occur at 37°C
for 1 hour. Complete medium was added to reach 106
cells/ml. The infected cells were further incubated for the
desired time. Cells were centrifuged, washed twice with
PBS; 1/5 were used for qPCR, and 4/5 for luciferase assay.
The infected cells were resuspended in 100 μl 1X Lysis
buffer (25 mM Tris, 2 mM DTT, 1% Triton X-100, 10%
glycerol) and luciferase activity was measured as described
above. 1/5 of the infected cells were lysed by resuspension
of cell pellets in 200 μl of qPCR lysis buffer containing
Tris–HCl, pH 8, 10 mM, and Polyoxyethylen 10 Lauryl-
ether 0.1% (Sigma, P-9769) [91]. Proteinase K was added
to a final concentration of 100 μg/ml and samples were
incubated at 65°C for 2 h followed by 15 min at 95°C. The
obtained extracts were directly used for qPCR of HIV pro-
moter for quantification of proviral copy number (sense :
5’-CTGCTGACATCGAGCTTTCTACAAGGG-3; re-
verse: 5’-AGGCTCAGATCTGGTCTAACCAGAGAG-3’).
To normalize for proviral content, standard samples of
known pNL4-3-LucE- copy number were included in each
qPCR run. 2 μl of extracts were used as template for qPCR
reaction, in a 20 μl reaction containing 150 nM of each
primer, 200 μM of each dNTP and 2U of KlenTaq in reac-
tion buffer (6 mM Tris–HCl pH 8.3, 25 mM KCl, 4 mM
MgCl2, 75 mM D+Trehalose dihydrate (Bioshop Canada),
0.1% Tween 20. 0.1 mg/ml BSA ,0,1X Sybr Green (Invitro-
gen, Eugene OR)). Primer sequences for mutated HIV












Primers were designed to create a double-stranded template for radioactive
labelling for use in EMSA or for direct cloning into XbaI and SphI sites. For
brevity only the positive strand oligos are shown. Bold face type indicates
nucleotides mutated from the wild type sequence.with human cells were conducted in accordance to the
Helsinki Declaration, with prior written consent from
donors, and as approved by the Ethics Committee of the
Université de Sherbrooke.
Additional files
Additional file 1: Figure S1. Quantification of complex intensity in EMSA
for Figures 4 and 5. Band intensity or entire lane intensity was quantified by
phosphorimager analysis of EMSA. (A) A table showing the percentage of
signal reduction for each PICH relative to its density in the control lane
containing no antibody (0) in Figure 4. ‘-’ indicates no signal reduction. Band
intensities that were reduced by one third (33%) or more relative to their
controls are highlighted in orange. (B) Graphic representation of the
intensity of the whole EMSA lane to show quantitative analysis of supershift
signals with antibody against AP4 (left panel, blue) and TFII-A (right panel,
pink) compared to the control with no antibody (black profile). Arrows and
colored interspaces between curves indicate the former and new position
of the supershifted band. The highest peak in the control is arbitrarily set to
100%. The peaks corresponding to PICH-3 and -2 are indicated as reference
points. (C) As in A, except quantification of Figure 5 is shown (EMSA with
HeLa NE). (D) As in B except quantification of Figure 5 is shown (EMSA with
HeLa NE).
Additional file 2: Figure S2. PICH and canonical PIC are differentially
affected by antibodies directed against TFIID subunits. EMSA were
performed as in Figure 2. Radiolabelled wt HIV promoter (lanes 1-4) or MLP
(lanes 5-8) were used as probes. Indicated specific antibodies directed
against general transcription factors were added to the EMSA reaction for
supershift assays. Pre-Initiation Complexes of HIV (PICHs) are indicated at the
left of the first panel. Complexes formed on AdMLP (unnamed) are
indicated by arrows on the left of the second panel.
Additional file 3: Figure S3. Validation of point mutations that enhance
or block USF-1 binding to TASHET. EMSAs were performed as in Figure 2.
(A) Radiolabelled wt HIV promoter was incubated with HeLa nuclear extracts
with or without addition of increasing amounts of unlabelled competitor :
20 (lanes 2, 5, 8), 60 (lanes 3, 6, 9) and 200 (lanes 4, 7, 10) fold molar excess
of the indicated competitors were added to the reaction. (B) The intensity of
the PICH-2 (left panel) and USF-1 (right panel) bands have been measured
on the phosphorimager analysis of EMSA from panel A and the relative
amount of these two complexes have been calculated. Results are
expressed starting with the intensity without competitor being set to 1. The
relative complex intensity in presence of wt HIV promoter competitor is
shown with a black line, as is that in the presence of USF-1+ competitor
(green line) and with USF-1KO competitor (red line). The triangle on the
horizontal axis stands for 20, 60 and 200 fold molar excess of competitor
versus radiolabelled probe.
Additional file 4: Figure S4. Quantification of complex intensity in EMSA
for Figures 7 and 8. The intensity of the EMSA bands was quantified using
phosphorimaging. Values in the tables express the percentage of signal
reduction for each PIC relative to its density in the control lane of the EMSA.
‘-’ indicates no signal reduction. (A) Quantification of EMSA in Figure 7. PICH
intensities that were reduced by one half (50%) or more relative to their
controls are highlighted in red. (B) Quantification of EMSA in Figure 8. PICH
intensities that were reduced by one third (33%) or more relative to their
controls are highlighted in orange.
Additional file 5: Figure S5. Mutations in TASHET do not affect the
transcription start site position. (A) HeLa cells were co-transfected with a
Tat expression plasmid and a plasmid expressing Renilla luciferase under
the control of HIV wt (lane 4) or mutated promoter (lanes 5 to 11). RNAs
have been extracted 24h after transfection and used in primer extension
assays. Lane 2 contains only the primer, lane 3 a primer extension on
untransfected HeLa RNA. Lane 1 contains the ladder whose sizes are
indicated at the left. The major transcript corresponding to the expected
start site is indicated by +1. (B) As in panel A, but in the absence of Tat.
Additional file 6: Figure S6. TAR RNA does not affect PIC on the
AdMLP or HIV with mutated CTGC motifs. EMSA were performed as in
Figure 2. HIV wt promoter (lanes 1-4), AdMLP (lanes 5-8) and CTGC5’3’
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transcribed TAR RNA were added as competitors as indicated.
Additional file 7: Figure S7. 7SK snRNA is not required for PICH
binding to TASHET. EMSA were performed as in Figure 2 except that
HeLa nuclear extract was pre-incubated with increasing amounts (5, 50
and 500ng as symbolized by the triangle) of antisense oligonucleotide
specific (221-241A) or non specific (221-241S) to 7SKsnRNA, after which
RNase H was added to digest the RNA-DNA duplex that may have been
formed. Reaction was then further performed as usual for EMSA and was
divided in two when ready for electrophoresis. (A) EMSA followed by
autoradiography on one half of the reaction and (B) qPCR of 7SK snRNA
and U6 snRNA as a control on the other half.
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